|
1
|
Herrlinger U: News on the horizon in
glioblastoma therapy. ESMO Open. 5(e000601)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Schaff LR and Mellinghoff IK: Glioblastoma
and other primary brain malignancies in adults: A review. JAMA.
329:574–587. 2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Delavar A, Wali AR, Santiago-Dieppa DR, Al
Jammal OM, Kidwell RL and Khalessi AA: Racial and ethnic
disparities in brain tumor survival by age group and tumor type. Br
J Neurosurg. 36:705–711. 2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-Year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Luo C, Song K, Wu S, Hameed NUF, Kudulaiti
N, Xu H, Qin ZY and Wu JS: The prognosis of glioblastoma: A large,
multifactorial study. Br J Neurosurg. 35:555–561. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Yabo YA, Niclou SP and Golebiewska A:
Cancer cell heterogeneity and plasticity: A paradigm shift in
glioblastoma. Neuro Oncol. 24:669–682. 2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bikfalvi A, da Costa CA, Avril T, Barnier
JV, Bauchet L, Brisson L, Cartron PF, Castel H, Chevet E,
Chneiweiss H, et al: Challenges in glioblastoma research: Focus on
the tumor microenvironment. Trends Cancer. 9:9–27. 2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Huang M, Zhang D, Wu JY, Xing K, Yeo E, Li
C, Zhang L, Holland E, Yao L, Qin L, et al: Wnt-mediated
endothelial transformation into mesenchymal stem cell-like cells
induces chemoresistance in glioblastoma. Sci Transl Med.
12(eaay7522)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Barzegar Behrooz A, Talaie Z, Jusheghani
F, Łos MJ, Klonisch T and Ghavami S: Wnt and PI3K/Akt/mTOR survival
pathways as therapeutic targets in glioblastoma. Int J Mol Sci.
23(1353)2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Behrooz AB and Syahir A: Could we address
the interplay between CD133, Wnt/β-catenin, and TERT signaling
pathways as a potential target for glioblastoma therapy? Front
Oncol. 11(642719)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Crunkhorn S: Targeting drug-resistant
glioblastoma. Nat Rev Drug Discov. 21(711)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Precilla DS, Kuduvalli SS, Purushothaman
M, Marimuthu P, Muralidharan AR and Anitha TS: Wnt/β-catenin
antagonists: Exploring new avenues to trigger old drugs in
alleviating glioblastoma multiforme. Curr Mol Pharmacol.
15:338–360. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yuan B, Wang G, Tang X, Tong A and Zhou L:
Immunotherapy of glioblastoma: Recent advances and future
prospects. Hum Vaccin Immunother. 18(2055417)2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Youngblood MW, Stupp R and Sonabend AM:
Role of Resection in glioblastoma management. Neurosurg Clin N Am.
32:9–22. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
De Biase G, Garcia DP, Bohnen A and
Quiñones-Hinojosa A: Perioperative management of patients with
glioblastoma. Neurosurg Clin N Am. 32:1–8. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lu VM, Goyal A, Graffeo CS, Perry A, Burns
TC, Parney IF, Quinones-Hinojosa A and Chaichana KL: Survival
benefit of maximal resection for glioblastoma reoperation in the
temozolomide era: A meta-analysis. World Neurosurg. 127:31–37.
2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Robin AM, Lee I and Kalkanis SN:
Reoperation for recurrent glioblastoma multiforme. Neurosurg Clin N
Am. 28:407–428. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Liang C, Gong J, Zhang B, Meng Z, Li M and
Guo Y: Multiple subtentorial metastasis in diffuse midline glioma
receiving tumor treating fields: A case report and literature
review. Ann Transl Med. 9(1604)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chen J, Shi Q, Li S, Zhao Y and Huang H:
Clinical characteristics of glioblastoma with metastatic spinal
dissemination. Ann Palliat Med. 11:506–512. 2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shah AH, Mahavadi A, Di L, Sanjurjo A,
Eichberg DG, Borowy V, Figueroa J, Luther E, de la Fuente MI,
Semonche A, et al: Survival benefit of lobectomy for glioblastoma:
Moving towards radical supramaximal resection. J Neurooncol.
148:501–508. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ryan JT, Nakayama M, Gleeson I, Mannion L,
Geso M, Kelly J, Ng SP and Hardcastle N: Functional brain imaging
interventions for radiation therapy planning in patients with
glioblastoma: A systematic review. Radiat Oncol.
17(178)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ylanan AMD, Pascual JSG, Cruz-Lim EMD,
Ignacio KHD, Cañal JPA and Khu KJO: Intraoperative radiotherapy for
glioblastoma: A systematic review of techniques and outcomes. J
Clin Neurosci. 93:36–41. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Khan L, Soliman H, Sahgal A, Perry J, Xu W
and Tsao MN: External beam radiation dose escalation for high grade
glioma. Cochrane Database Syst Rev. 5(CD011475)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Barbarite E, Sick JT, Berchmans E, Bregy
A, Shah AH, Elsayyad N and Komotar RJ: The role of brachytherapy in
the treatment of glioblastoma multiforme. Neurosurg Rev.
40:195–211. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Vogelius IR and Bentzen SM: Proton vs
photon radiation therapy for glioblastoma: Maximizing information
from trial. Neuro Oncol. 24:849–850. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Malouff TD, Seneviratne DS, Ebner DK,
Stross WC, Waddle MR, Trifiletti DM and Krishnan S: Boron Neutron
capture therapy: A review of clinical applications. Front Oncol.
11(601820)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Laprie A, Tensaouti F and Cohen-Jonathan
Moyal E: Radiation dose intensification for glioblastoma. Cancer
Radiother. 26:894–898. 2022.PubMed/NCBI View Article : Google Scholar : (In French).
|
|
28
|
Tan AC, Ashley DM, López GY, Malinzak M,
Friedman HS and Khasraw M: Management of glioblastoma: State of the
art and future directions. CA Cancer J Clin. 70:299–312.
2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Woodroffe RW, Zanaty M, Soni N, Mott SL,
Helland LC, Pasha A, Maley J, Dhungana N, Jones KA, Monga V and
Greenlee JDW: Survival after reoperation for recurrent
glioblastoma. J Clin Neurosci. 73:118–124. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zakaria R and Weinberg JS: Challenges
associated with reoperation in patients with glioma. Neurosurg Clin
N Am. 32:129–135. 2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Mathen P, Rowe L, Mackey M, Smart D,
Tofilon P and Camphausen K: Radiosensitizers in the temozolomide
era for newly diagnosed glioblastoma. Neurooncol Pract. 7:268–276.
2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Herrlinger U, Tzaridis T, Mack F,
Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D,
Grauer O, et al: Lomustine-temozolomide combination therapy versus
standard temozolomide therapy in patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): A
randomised, open-label, phase 3 trial. Lancet. 393:678–688.
2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Hwang K, Lee JH, Kim SH, Go KO, Ji SY, Han
JH and Kim CY: The combination PARP inhibitor olaparib with
temozolomide in an experimental glioblastoma model. In Vivo.
35:2015–2023. 2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Nguyen TTT, Zhang Y, Shang E, Shu C,
Torrini C, Zhao J, Bianchetti E, Mela A, Humala N, Mahajan A, et
al: HDAC inhibitors elicit metabolic reprogramming by targeting
super-enhancers in glioblastoma models. J Clin Invest.
130:3699–3716. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Bindra RS: Penetrating the brain tumor
space with DNA damage response inhibitors. Neuro Oncol.
22:1718–1720. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhao J, Yang S, Cui X, Wang Q, Yang E,
Tong F, Hong B, Xiao M, Xin L, Xu C, et al: A novel compound
EPIC-0412 reverses temozolomide resistance via inhibiting DNA
repair/MGMT in glioblastoma. Neuro Oncol. 25:857–870.
2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Goel NJ, Bird CE, Hicks WH and Abdullah
KG: Economic implications of the modern treatment paradigm of
glioblastoma: An analysis of global cost estimates and their
utility for cost assessment. J Med Econ. 24:1018–1024.
2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lauko A, Lo A, Ahluwalia MS and Lathia JD:
Cancer cell heterogeneity & plasticity in glioblastoma and
brain tumors. Semin Cancer Biol. 82:162–175. 2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Oliver L, Lalier L, Salaud C, Heymann D,
Cartron PF and Vallette FM: Drug resistance in glioblastoma: Are
persisters the key to therapy? Cancer Drug Resist. 3:287–301.
2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Verhaak RG, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al:
Integrated genomic analysis identifies clinically relevant subtypes
of glioblastoma characterized by abnormalities in PDGFRA, IDH1,
EGFR, and NF1. Cancer Cell. 17:98–110. 2010.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Steponaitis G and Tamasauskas A:
Mesenchymal and proneural subtypes of glioblastoma disclose
branching based on GSC associated signature. Int J Mol Sci.
22(4964)2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Brennan CW, Verhaak RG, McKenna A, Campos
B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ,
Berman SH, et al: The somatic genomic landscape of glioblastoma.
Cell. 155:462–477. 2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Melhem JM, Detsky J, Lim-Fat MJ and Perry
JR: Updates in IDH-wildtype glioblastoma. Neurotherapeutics.
19:1705–1723. 2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
French R and Pauklin S: Epigenetic
regulation of cancer stem cell formation and maintenance. Int J
Cancer. 148:2884–2897. 2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Capper D, Stichel D, Sahm F, Jones DTW,
Schrimpf D, Sill M, Schmid S, Hovestadt V, Reuss DE, Koelsche C, et
al: Practical implementation of DNA methylation and
copy-number-based CNS tumor diagnostics: The Heidelberg experience.
Acta Neuropathol. 136:181–210. 2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Neftel C, Laffy J, Filbin MG, Hara T,
Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM,
et al: An integrative model of cellular states, plasticity, and
genetics for glioblastoma. Cell. 178:835–849.e21. 2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Garofano L, Migliozzi S, Oh YT, D'Angelo
F, Najac RD, Ko A, Frangaj B, Caruso FP, Yu K, Yuan J, et al:
Pathway-based classification of glioblastoma uncovers a
mitochondrial subtype with therapeutic vulnerabilities. Nat Cancer.
2:141–156. 2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Hubert CG and Lathia JD: Seeing the GBM
diversity spectrum. Nat Cancer. 2:135–137. 2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Richards LM, Whitley OKN, MacLeod G,
Cavalli FMG, Coutinho FJ, Jaramillo JE, Svergun N, Riverin M,
Croucher DC, Kushida M, et al: Gradient of developmental and injury
response transcriptional states defines functional vulnerabilities
underpinning glioblastoma heterogeneity. Nat Cancer. 2:157–173.
2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Ensenyat-Mendez M, Íñiguez-Muñoz S, Sesé B
and Marzese DM: iGlioSub: An integrative transcriptomic and
epigenomic classifier for glioblastoma molecular subtypes. BioData
Min. 14(42)2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Wang LB, Karpova A, Gritsenko MA, Kyle JE,
Cao S, Li Y, Rykunov D, Colaprico A, Rothstein JH, Hong R, et al:
Proteogenomic and metabolomic characterization of human
glioblastoma. Cancer Cell. 39:509–528.e20. 2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Drakulic D, Schwirtlich M, Petrovic I,
Mojsin M, Milivojevic M, Kovacevic-Grujicic N and Stevanovic M:
Current opportunities for targeting dysregulated neurodevelopmental
signaling pathways in glioblastoma. Cells. 11(2530)2022.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Walcher L, Kistenmacher AK, Suo H, Kitte
R, Dluczek S, Strauß A, Blaudszun AR, Yevsa T, Fricke S and
Kossatz-Boehlert U: Cancer stem cells-origins and biomarkers:
Perspectives for targeted personalized therapies. Front Immunol.
11(1280)2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Bryukhovetskiy A, Shevchenko V, Kovalev S,
Chekhonin V, Baklaushev V, Bryukhovetskiy I and Zhukova M: To the
novel paradigm of proteome-based cell therapy of tumors: Through
comparative proteome mapping of tumor stem cells and
tissue-specific stem cells of humans. Cell Transplant. 23 (Suppl
1):S151–S170. 2014.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Bryukhovetskiy IS, Dyuizen IV, Shevchenko
VE, Bryukhovetskiy AS, Mischenko PV, Milkina EV and Khotimchenko
YS: Hematopoietic stem cells as a tool for the treatment of
glioblastoma multiforme. Mol Med Rep. 14:4511–4520. 2016.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Couturier CP, Nadaf J, Li Z, Baig S, Riva
G, Le P, Kloosterman DJ, Monlong J, Nkili Meyong A, Allache R, et
al: Glioblastoma scRNA-seq shows treatment-induced,
immune-dependent increase in mesenchymal cancer cells and
structural variants in distal neural stem cells. Neuro Oncol.
24:1494–1508. 2022.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Wang X, Zhou R, Xiong Y, Zhou L, Yan X,
Wang M, Li F, Xie C, Zhang Y, Huang Z, et al: Sequential
fate-switches in stem-like cells drive the tumorigenic trajectory
from human neural stem cells to malignant glioma. Cell Res.
31:684–702. 2021.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Mizrak D, Brittan M and Alison M: CD133:
Molecule of the moment. J Pathol. 214:3–9. 2008.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Zheng Y, Wang L, Yin L, Yao Z, Tong R, Xue
J and Lu Y: Lung cancer stem cell markers as therapeutic targets:
An update on signaling pathways and therapies. Front Oncol.
12(873994)2022.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Park J, Kim SK, Hallis SP, Choi BH and
Kwak MK: Role of CD133/NRF2 axis in the development of colon cancer
stem cell-like properties. Front Oncol. 11(808300)2022.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Hefni AM, Sayed AM, Hussien MT, Abdalla AZ
and Gabr AG: CD133 is an independent predictive and prognostic
marker in metastatic breast cancer. Cancer Biomark. 35:207–215.
2022.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Gimple RC, Bhargava S, Dixit D and Rich
JN: Glioblastoma stem cells: Lessons from the tumor hierarchy in a
lethal cancer. Genes Dev. 33:591–609. 2019.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Beier CP and Beier D: CD133 negative
cancer stem cells in glioblastoma. Front Biosci (Elite Ed).
3:701–710. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
66
|
Wang Z, Zhang H, Xu S, Liu Z and Cheng Q:
The adaptive transition of glioblastoma stem cells and its
implications on treatments. Signal Transduct Target Ther.
6(124)2021.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Xie XP, Laks DR, Sun D, Ganbold M, Wang Z,
Pedraza AM, Bale T, Tabar V, Brennan C, Zhou X and Parada LF:
Quiescent human glioblastoma cancer stem cells drive tumor
initiation, expansion, and recurrence following chemotherapy. Dev
Cell. 57:32–46.e8. 2022.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Liu J, Gao L, Zhan N, Xu P, Yang J, Yuan
F, Xu Y, Cai Q, Geng R and Chen Q: Hypoxia induced ferritin light
chain (FTL) promoted epithelia mesenchymal transition and
chemoresistance of glioma. J Exp Clin Cancer Res.
39(137)2020.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Gao L, Tong S, Liu J, Cai J, Ye Z, Zhou L,
Song P, Li Z, Lei P, Wei H, et al: TMEM2 induces
epithelial-mesenchymal transition and promotes resistance to
temozolomide in GBM cells. Heliyon. 9(e16559)2023.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Zhang X, Wang X, Xu R, Ji J, Xu Y, Han M,
Wei Y, Huang B, Chen A, Zhang Q, et al: YM155 decreases
radiation-induced invasion and reverses epithelial-mesenchymal
transition by targeting STAT3 in glioblastoma. J Transl Med.
16(79)2018.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Zhang X, Wang X, Xu R, Ji J, Xu Y, Han M,
Wei Y, Huang B, Chen A, Zhang Q, et al: Correction to: YM155
decreases radiation-induced invasion and reverses
epithelial-mesenchymal transition by targeting STAT3 in
glioblastoma. J Transl Med. 19(407)2021.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Huang W, Zhang C, Cui M, Niu J and Ding W:
Inhibition of bevacizumab-induced epithelial-mesenchymal transition
by BATF2 overexpression involves the suppression of Wnt/β-catenin
signaling in glioblastoma cells. Anticancer Res. 37:4285–4294.
2017.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Coelho BP, Fernandes CFL, Boccacino JM,
Souza MCDS, Melo-Escobar MI, Alves RN, Prado MB, Iglesia RP,
Cangiano G, Mazzaro GR and Lopes MH: Multifaceted WNT signaling at
the crossroads between epithelial-mesenchymal transition and
autophagy in glioblastoma. Front Oncol. 10(597743)2020.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Alkailani MI, Aittaleb M and Tissir F: WNT
signaling at the intersection between neurogenesis and brain
tumorigenesis. Front Mol Neurosci. 15(1017568)2022.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Rajakulendran N, Rowland KJ, Selvadurai
HJ, Ahmadi M, Park NI, Naumenko S, Dolma S, Ward RJ, So M, Lee L,
et al: Wnt and Notch signaling govern self-renewal and
differentiation in a subset of human glioblastoma stem cells. Genes
Dev. 33:498–510. 2019.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Rim EY, Clevers H and Nusse R: The Wnt
pathway: From signaling mechanisms to synthetic modulators. Annu
Rev Biochem. 91:571–598. 2022.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Sareddy GR, Pratap UP, Viswanadhapalli S,
Venkata PP, Nair BC, Krishnan SR, Zheng S, Gilbert AR, Brenner AJ,
Brann DW and Vadlamudi RK: PELP1 promotes glioblastoma progression
by enhancing Wnt/β-catenin signaling. Neurooncol Adv.
1(vdz042)2019.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Latour M, Her NG, Kesari S and Nurmemmedov
E: WNT signaling as a therapeutic target for glioblastoma. Int J
Mol Sci. 22(8428)2021.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Tang C, Guo J, Chen H, Yao CJ, Zhuang DX,
Wang Y, Tang WJ, Ren G, Yao Y, Wu JS, et al: Gene mutation
profiling of primary glioblastoma through multiple tumor biopsy
guided by 1H-magnetic resonance spectroscopy. Int J Clin Exp
Pathol. 8:5327–5335. 2015.PubMed/NCBI
|
|
80
|
Morris LG, Ramaswami D and Chan TA: The
FAT epidemic: A gene family frequently mutated across multiple
human cancer types. Cell Cycle. 12:1011–1012. 2013.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Fargeas CA, Lorico A and Corbeil D:
Commentary: Could we address the interplay between CD133,
Wnt/β-catenin, and TERT signaling pathways as a potential target
for glioblastoma therapy? Front Oncol. 11(712358)2021.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Shevchenko V, Arnotskaya N, Zaitsev S,
Sharma A, Sharma HS, Bryukhovetskiy A, Pak O, Khotimchenko Y and
Bryukhovetskiy I: Proteins of Wnt signaling pathway in cancer stem
cells of human glioblastoma. Int Rev Neurobiol. 151:185–200.
2020.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Manoranjan B, Chokshi C, Venugopal C,
Subapanditha M, Savage N, Tatari N, Provias JP, Murty NK, Moffat J,
Doble BW and Singh SK: A CD133-AKT-Wnt signaling axis drives
glioblastoma brain tumor-initiating cells. Oncogene. 39:1590–1599.
2020.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Jhanwar-Uniyal M, Wainwright JV, Mohan AL,
Tobias ME, Murali R, Gandhi CD and Schmidt MH: Diverse signaling
mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a
formidable relationship. Adv Biol Regul. 72:51–62. 2019.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Shahcheraghi SH, Tchokonte-Nana V, Lotfi
M, Lotfi M, Ghorbani A and Sadeghnia HR: Wnt/beta-catenin and
PI3K/Akt/mTOR signaling pathways in glioblastoma: Two main targets
for drug design: A review. Curr Pharm Des. 26:1729–1741.
2020.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Liu N, Guo XH, Liu JP and Cong YS: Role of
telomerase in the tumor microenvironment. Clin Exp Pharmacol
Physiol. 47:357–364. 2020.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Abad E, Graifer D and Lyakhovich A: DNA
damage response and resistance of cancer stem cells. Сancer Lett.
474:106–117. 2020.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Fan D, Yue Q, Chen J, Wang C, Yu R, Jin Z,
Yin S, Wang Q, Chen L, Liao X, et al: Reprogramming the
immunosuppressive microenvironment of IDH1 wild-type glioblastoma
by blocking Wnt signaling between microglia and cancer cells.
Oncoimmunology. 10(1932061)2021.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Hao J, Han X, Huang H, Yu X, Fang J, Zhao
J, Prayson RA, Bao S and Yu JS: Sema3C signaling is an alternative
activator of the canonical WNT pathway in glioblastoma. Nat Commun.
14(2262)2023.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Montemurro N, Pahwa B, Tayal A, Shukla A,
De Jesus Encarnacion M, Ramirez I, Nurmukhametov R, Chavda V and De
Carlo A: Macrophages in recurrent glioblastoma as a prognostic
factor in the synergistic system of the tumor microenvironment.
Neurol Int. 15:595–608. 2023.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Chan MK, Chung JY, Tang PC, Chan AS, Ho
JY, Lin TP, Chen J, Leung KT, To KF, Lan HY and Tang PM: TGF-β
signaling networks in the tumor microenvironment. Cancer Lett.
550(215925)2022.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Yun EJ, Kim S, Hsieh JT and Baek ST:
Wnt/β-catenin signaling pathway induces autophagy-mediated
temozolomide-resistance in human glioblastoma. Cell Death Dis.
11(771)2020.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Matias D, Predes D, Niemeyer Filho P,
Lopes MC, Abreu JG, Lima FRS and Moura Neto V:
Microglia-glioblastoma interactions: New role for Wnt signaling.
Biochim Biophys Acta Rev Cancer. 1868:333–340. 2017.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Tao W, Chu C, Zhou W, Huang Z, Zhai K,
Fang X, Huang Q, Zhang A, Wang X, Yu X, et al: Dual role of WISP1
in maintaining glioma stem cells and tumor-supportive macrophages
in glioblastoma. Nat Commun. 11(3015)2020.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Bayik D and Lathia JD: Cancer stem
cell-immune cell crosstalk in tumor progression. Nat Rev Cancer.
21:526–536. 2021.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Omuro A: Immune-checkpoint inhibitors for
glioblastoma: What have we learned? Arq Neuropsiquiatr. 80 (5 Suppl
1):S266–S269. 2022.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Verdugo E, Puerto I and Medina MÁ: An
update on the molecular biology of glioblastoma, with clinical
implications and progress in its treatment. Cancer Commun (Lond).
42:1083–1111. 2022.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Sautter L, Hofheinz R, Tuettenberg J,
Grimm M, Vajkoczy P, Groden C, Schmieder K, Hochhaus A, Wenz F and
Giordano FA: Open-label phase II evaluation of imatinib in primary
inoperable or incompletely resected and recurrent glioblastoma.
Oncology. 98:16–22. 2020.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Kim JY, Jo Y, Oh HK and Kim EH: Sorafenib
increases tumor treating fields-induced cell death in glioblastoma
by inhibiting STAT3. Am J Cancer Res. 10:3475–3486. 2020.PubMed/NCBI
|
|
100
|
Alamón C, Dávila B, García MF, Sánchez C,
Kovacs M, Trias E, Barbeito L, Gabay M, Zeineh N, Gavish M, et al:
Sunitinib-containing carborane pharmacophore with the ability to
inhibit tyrosine kinases receptors FLT3, KIT and PDGFR-β, exhibits
powerful in vivo anti-glioblastoma activity. Cancers (Basel).
12(3423)2020.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Reardon DA, Desjardins A, Vredenburgh JJ,
O'Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV,
et al: Rindopepimut with bevacizumab for patients with relapsed
EGFRvIII-expressing glioblastoma (ReACT): Results of a double-blind
randomized phase II trial. Clin Cancer Res. 26:1586–1594.
2020.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Padovan M, Eoli M, Pellerino A, Rizzato S,
Caserta C, Simonelli M, Michiara M, Caccese M, Anghileri E,
Cerretti G, et al: Depatuxizumab mafodotin (Depatux-M) plus
temozolomide in recurrent glioblastoma patients: Real-world
experience from a multicenter study of italian association of
neuro-oncology (AINO). Cancers (Basel). 13(2773)2021.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Lassman AB, Pugh SL, Wang TJC, Aldape K,
Gan HK, Preusser M, Vogelbaum MA, Sulman EP, Won M, Zhang P, et al:
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed
glioblastoma: A phase III randomized clinical trial. Neuro Oncol.
25:339–350. 2023.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Cloughesy T, Finocchiaro G, Belda-Iniesta
C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C,
Macdonald DR, et al: Randomized, double-blind, placebo-controlled,
multicenter phase II study of onartuzumab plus bevacizumab versus
placebo plus bevacizumab in patients with recurrent glioblastoma:
efficacy, safety, and hepatocyte growth factor and
O6-methylguanine-DNA methyltransferase biomarker
analyses. J Clin Oncol. 35:343–351. 2017.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Cloughesy TF, Drappatz J, de Groot J,
Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T,
Desjardins A, Ping J, et al: Phase II study of cabozantinib in
patients with progressive glioblastoma: Subset analysis of patients
with prior antiangiogenic therapy. Neuro Oncol. 20:259–267.
2018.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Zhang T, Xin Q and Kang JM: Bevacizumab
for recurrent glioblastoma: A systematic review and meta-analysis.
Eur Rev Med Pharmacol Sci. 25:6480–6491. 2021.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Wen PY, Rodon JA, Mason W, Beck JT,
DeGroot J, Donnet V, Mills D, El-Hashimy M and Rosenthal M: Phase
I, open-label, multicentre study of buparlisib in combination with
temozolomide or with concomitant radiation therapy and temozolomide
in patients with newly diagnosed glioblastoma. ESMO Open.
5(e000673)2020.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Rosenthal M, Clement PM, Campone M,
Gil-Gil MJ, DeGroot J, Chinot O, Idbaih A, Gan H, Raizer J, Wen PY,
et al: Buparlisib plus carboplatin or lomustine in patients with
recurrent glioblastoma: A phase Ib/II, open-label, multicentre,
randomised study. ESMO Open. 5(e000672)2020.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Kaley TJ, Panageas KS, Pentsova EI,
Mellinghoff IK, Nolan C, Gavrilovic I, DeAngelis LM, Abrey LE,
Holland EC, Omuro A, et al: Phase I clinical trial of temsirolimus
and perifosine for recurrent glioblastoma. Ann Clin Transl Neurol.
7:429–436. 2020.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Schiff D, Jaeckle KA, Anderson SK, Galanis
E, Giannini C, Buckner JC, Stella P, Flynn PJ, Erickson BJ,
Schwerkoske JF, et al: Phase 1/2 trial of temsirolimus and
sorafenib in the treatment of patients with recurrent glioblastoma:
North central cancer treatment group study/alliance N0572. Cancer.
124:1455–1463. 2018.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Lin Z, Xu H, Yang R, Li Z, Zheng H, Zhang
Z, Peng J, Zhang X, Qi S, Liu Y and Huang G: Effective treatment of
a BRAF V600E-mutant epithelioid glioblastoma patient by
vemurafenib: a case report. Anticancer Drugs. 33:100–104.
2022.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Herrera-Rios D, Li G, Khan D, Tsiampali J,
Nickel AC, Aretz P, Hewera M, Suwala AK, Jiang T, Steiger HJ, et
al: A computational guided, functional validation of a novel
therapeutic antibody proposes Notch signaling as a clinical
relevant and druggable target in glioma. Sci Rep.
10(16218)2020.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Bogdahn U, Hau P, Stockhammer G,
Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S,
Oliushine V, Parfenov V, et al: Targeted therapy for high-grade
glioma with the TGF-β2 inhibitor trabedersen: Results of a
randomized and controlled phase IIb study. Neuro Oncol. 13:132–142.
2011.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Hadizadeh M, AminJafari A, Parvizpour S
and Ghasemi S: Novel targets to overcome antiangiogenesis therapy
resistance in glioblastoma multiforme: Systems biology approach and
suggestion of therapy by galunisertib. Cell Biol Int. 46:1649–1660.
2022.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Wick A, Desjardins A, Suarez C, Forsyth P,
Gueorguieva I, Burkholder T, Cleverly AL, Estrem ST, Wang S, Lahn
MM, et al: Phase 1b/2a study of galunisertib, a small molecule
inhibitor of transforming growth factor-beta receptor I, in
combination with standard temozolomide-based radiochemotherapy in
patients with newly diagnosed malignant glioma. Invest New Drugs.
38:1570–1579. 2020.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Hsu SY, Lee SC, Liu HC, Peng SF, Chueh FS,
Lu TJ, Lee HT and Chou YC: Phenethyl isothiocyanate suppresses the
proinflammatory cytokines in human glioblastoma cells through the
PI3K/Akt/NF-κB signaling pathway in vitro. Oxid Med Cell Longev.
2022(2108289)2022.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Li S, He Y, Chen K, Sun J, Zhang L, He Y,
Yu H and Li Q: RSL3 drives ferroptosis through NF-κB pathway
activation and GPX4 depletion in glioblastoma. Oxid Med Cell
Longev. 2021(2915019)2021.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Volmar MNM, Cheng J, Alenezi H, Richter S,
Haug A, Hassan Z, Goldberg M, Li Y, Hou M, Herold-Mende C, et al:
Cannabidiol converts NF-κB into a tumor suppressor in glioblastoma
with defined antioxidative properties. Neuro Oncol. 23:1898–1910.
2021.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Navone SE, Guarnaccia L, Cordiglieri C,
Crisà FM, Caroli M, Locatelli M, Schisano L, Rampini P, Miozzo M,
La Verde N, et al: Aspirin affects tumor angiogenesis and
sensitizes human glioblastoma endothelial cells to temozolomide,
bevacizumab, and sunitinib, impairing vascular endothelial growth
factor-related signaling. World Neurosurg. 120:e380–e391.
2018.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Kast RE: Adding high-dose celecoxib to
increase effectiveness of standard glioblastoma chemoirradiation.
Ann Pharm Fr. 79:481–488. 2021.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Yin D, Jin G, He H, Zhou W, Fan Z, Gong C,
Zhao J and Xiong H: Celecoxib reverses the glioblastoma
chemo-resistance to temozolomide through mitochondrial metabolism.
Aging (Albany NY). 13:21268–21282. 2021.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Pantovic A, Bosnjak M, Arsikin K, Kosic M,
Mandic M, Ristic B, Tosic J, Grujicic D, Isakovic A, Micic N, et
al: In vitro antiglioma action of indomethacin is mediated via
AMP-activated protein kinase/mTOR complex 1 signalling pathway. Int
J Biochem Cell Biol. 83:84–96. 2017.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Allani SK, Weissbach H and Lopez Toledano
MA: Sulindac induces differentiation of glioblastoma stem cells
making them more sensitive to oxidative stress. Neoplasma.
65:376–388. 2018.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Qiu J, Shi Z and Jiang J: Cyclooxygenase-2
in glioblastoma multiforme. Drug Discov Today. 22:148–156.
2017.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Li H, Jiao S, Li X, Banu H, Hamal S and
Wang X: Therapeutic effects of antibiotic drug tigecycline against
cervical squamous cell carcinoma by inhibiting Wnt/β-catenin
signaling. Biochem Biophys Res Commun. 467:14–20. 2015.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Wieland A, Trageser D, Gogolok S, Reinartz
R, Höfer H, Keller M, Leinhaas A, Schelle R, Normann S, Klaas L, et
al: Anticancer effects of niclosamide in human glioblastoma. Clin
Cancer Res. 19:4124–4136. 2013.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Li H, Liu S, Jin R, Xu H, Li Y, Chen Y and
Zhao G: Pyrvinium pamoate regulates MGMT expression through
suppressing the Wnt/β-catenin signaling pathway to enhance the
glioblastoma sensitivity to temozolomide. Cell Death Discov.
7(288)2021.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Liu Y, Fang S, Sun Q and Liu B:
Anthelmintic drug ivermectin inhibits angiogenesis, growth and
survival of glioblastoma through inducing mitochondrial dysfunction
and oxidative stress. Biochem Biophys Res Commun. 480:415–421.
2016.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Hajikhani B, Nasiri MJ, Hosseini SS,
Khalili F, Karimi-Yazdi M, Hematian A, Nojookambari NY, Goudarzi M,
Dadashi M and Mirsaeidi M: Clofazimine susceptibility testing of
Mycobacterium avium complex and Mycobacterium abscessus: A
meta-analysis study. J Glob Antimicrob Resist. 26:188–193.
2021.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Park L, Wallace CE, Vasile G and Buckley
C: A case of lepromatous leprosy with erythema nodosum leprosum.
Cureus. 15(e33846)2023.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Ahmed K, Koval A, Xu J, Bodmer A and
Katanaev VL: Towards the first targeted therapy for triple-negative
breast cancer: Repositioning of clofazimine as a
chemotherapy-compatible selective Wnt pathway inhibitor. Cancer
Lett. 449:45–55. 2019.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Xu J, Koval A and Katanaev VL: Beyond
TNBC: Repositioning of clofazimine against a broad range of
Wnt-dependent cancers. Front Oncol. 10(602817)2020.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Keswani RK, Tian C, Peryea T, Girish G,
Wang X and Rosania GR: Repositioning clofazimine as a
macrophage-targeting photoacoustic contrast agent. Sci Rep.
6(23528)2016.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Trexel J, Yoon GS, Keswani RK, McHugh C,
Yeomans L, Vitvitsky V, Banerjee R, Sud S, Sun Y, Rosania GR and
Stringer KA: Macrophage-mediated clofazimine sequestration is
accompanied by a shift in host energy metabolism. J Pharm Sci.
106:1162–1174. 2017.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Yoon GS, Sud S, Keswani RK, Baik J,
Standiford TJ, Stringer KA and Rosania GR: Phagocytosed clofazimine
biocrystals can modulate innate immune signaling by inhibiting TNFα
and boosting IL-1RA secretion. Mol Pharm. 12:2517–2527.
2015.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Geribaldi-Doldán N, Fernández-Ponce C,
Quiroz RN, Sánchez-Gomar I, Escorcia LG, Velásquez EP and Quiroz
EN: The role of microglia in glioblastoma. Front Oncol.
10(603495)2021.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Castellani G, Croese T, Peralta Ramos JM
and Schwartz M: Transforming the understanding of brain immunity.
Science. 380(eabo7649)2023.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Rustenhoven J and Kipnis J: Brain borders
at the central stage of neuroimmunology. Nature. 612:417–429.
2022.PubMed/NCBI View Article : Google Scholar : De Leo A, Ugolini
A and Veglia F: Myeloid cells in glioblastoma microenvironment.
Cells 10: 18, 2020.
|
|
139
|
Lewellis SW and Knaut H: Attractive
guidance: How the chemokine SDF1/CXCL12 guides different cells to
different locations. Semin Cell Dev Biol. 23:333–340.
2012.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Giordano FA, Link B, Glas M, Herrlinger U,
Wenz F, Umansky V, Brown JM and Herskind C: Targeting the
post-irradiation tumor microenvironment in glioblastoma via
inhibition of CXCL12. Cancers (Basel). 11(272)2019.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Wang S, Chen C, Li J, Xu X, Chen W and Li
F: The CXCL12/CXCR4 axis confers temozolomide resistance to human
glioblastoma cells via up-regulation of FOXM1. J Neurol Sci.
414(116837)2020.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Dolina JS, Van Braeckel-Budimir N, Thomas
GD and Salek-Ardakani S: CD8+ T cell exhaustion in
cancer. Front Immunol. 12(715234)2021.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Belk JA, Daniel B and Satpathy AT:
Epigenetic regulation of T cell exhaustion. Nat Immunol.
23:848–860. 2022.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Yang T, Kong Z and Ma W: PD-1/PD-L1 immune
checkpoint inhibitors in glioblastoma: Clinical studies, challenges
and potential. Hum Vaccin Immunother. 17:546–553. 2021.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Arrieta VA, Dmello C, McGrail DJ, Brat DJ,
Lee-Chang C, Heimberger AB, Chand D, Stupp R and Sonabend AM:
Immune checkpoint blockade in glioblastoma: From tumor
heterogeneity to personalized treatment. J Clin Invest.
133(e163447)2023.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Caramanna I, de Kort JM, Brandes AA, Taal
W, Platten M, Idbaih A, Frenel JS, Wick W, Preetha CJ, Bendszus M,
et al: Corticosteroids use and neurocognitive functioning in
patients with recurrent glioblastoma: Evidence from European
organization for research and treatment of cancer (EORTC) trial
26101. Neurooncol Pract. 9:310–316. 2022.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Pitter KL, Tamagno I, Alikhanyan K,
Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, Ozawa T, Chang M,
Chan TA, et al: Corticosteroids compromise survival in
glioblastoma. Brain. 139:1458–1471. 2016.PubMed/NCBI View Article : Google Scholar
|
|
148
|
Klement RJ and Champ CE: Corticosteroids
compromise survival in glioblastoma in part through their elevation
of blood glucose levels. Brain. 140(e16)2017.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Yovino S, Kleinberg L, Grossman SA,
Narayanan M and Ford E: The etiology of treatment-related
lymphopenia in patients with malignant gliomas: Modeling radiation
dose to circulating lymphocytes explains clinical observations and
suggests methods of modifying the impact of radiation on immune
cells. Cancer Invest. 31:140–144. 2013.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Kut C and Kleinberg L: Radiotherapy,
lymphopenia and improving the outcome for glioblastoma: A narrative
review. Chin Clin Oncol. 12(4)2023.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Saito T, Sugiyama K, Hama S, Yamasaki F,
Takayasu T, Nosaka R, Muragaki Y, Kawamata T and Kurisu K:
Prognostic importance of temozolomide-induced neutropenia in
glioblastoma, IDH-wildtype patients. Neurosurg Rev. 41:621–628.
2018.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Aboody KS, Brown A, Rainov NG, Bower KA,
Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, et al:
Neural stem cells display extensive tropism for pathology in adult
brain: Evidence from intracranial gliomas. Proc Natl Acad Sci USA.
97:12846–12851. 2000.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Snyder EY, Park KI, Flax JD, Liu S,
Rosario CM, Yandava BD and Aurora S: Potential of neural
‘stem-like’ cells for gene therapy and repair of the degenerating
central nervous system. Adv Neurol. 72:121–132. 1997.PubMed/NCBI
|
|
154
|
Bryukhovetskiy IS, Mischenko PV, Tolok EV,
Zaitcev SV, Khotimchenko YS and Bryukhovetskiy AS: Directional
migration of adult hematopoeitic progenitors to C6 glioma in
vitro. Oncol Lett. 9:1839–1844. 2015.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Hass R, von der Ohe J and Dittmar T:
Hybrid formation and fusion of cancer cells in vitro and in vivo.
Cancers (Basel). 13(4496)2021.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Goldenberg DM: Horizontal transmission of
malignancy by cell-cell fusion. Expert Opin Biol Ther. 12 (Suppl
1):S133–S139. 2012.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Sun Z, Wang L, Zhou Y, Dong L, Ma W, Lv L,
Zhang J and Wang X: Glioblastoma stem cell-derived exosomes enhance
stemness and tumorigenicity of glioma cells by transferring Notch1
protein. Cell Mol Neurobiol. 40:767–784. 2020.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Khan F, Pang L, Dunterman M, Lesniak MS,
Heimberger AB and Chen P: Macrophages and microglia in
glioblastoma: Heterogeneity, plasticity, and therapy. J Clin
Invest. 133(e163446)2023.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Wang G, Zhong K, Wang Z, Zhang Z, Tang X,
Tong A and Zhou L: Tumor-associated microglia and macrophages in
glioblastoma: From basic insights to therapeutic opportunities.
Front Immunol. 13(964898)2022.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Bryukhovetskiy IS, Mischenko PV, Tolok EV,
Zaitcev SV, Khotimchenko YS and Bryukhovetskiy AS: Directional
migration of adult hematopoeitic progenitors to C6 glioma in
vitro. Oncol Lett. 9:1839–1844. 2015.PubMed/NCBI View Article : Google Scholar
|
|
161
|
Lee-Six H, Øbro NF, Shepherd MS, Grossmann
S, Dawson K, Belmonte M, Osborne RJ, Huntly BJP, Martincorena I,
Anderson E, et al: Population dynamics of normal human blood
inferred from somatic mutations. Nature. 561:473–478.
2018.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Jaiswal S: Clonal hematopoiesis and
nonhematologic disorders. Blood. 136:1606–1614. 2020.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Kast RE, Hill QA, Wion D, Mellstedt H,
Focosi D, Karpel-Massler G, Heiland T and Halatsch ME:
Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and
immunosuppression: Potential therapeutic benefit from dapsone,
fenofibrate, and ribavirin. Tumour Biol.
39(1010428317699797)2017.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Bryukhovetskiy I, Manzhulo I, Mischenko P,
Milkina E, Dyuizen I, Bryukhovetskiy A and Khotimchenko Y: Cancer
stem cells and microglia in the processes of glioblastoma
multiforme invasive growth. Oncol Lett. 12:1721–1728.
2016.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Zaitsev S, Sharma HS, Sharma A, Manzhulo
I, Polevshchikov A, Kudriavtsev I, Khotimchenko Y, Pak O,
Bryukhovetskiy A and Bryukhovetskiy I: Pro-inflammatory
modification of cancer cells microsurroundings increases the
survival rates for rats with low differentiated malignant glioma of
brain. Int Rev Neurobiol. 151:253–279. 2020.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Choe JH, Watchmaker PB, Simic MS, Gilbert
RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, et al:
SynNotch-CAR T cells overcome challenges of specificity,
heterogeneity, and persistence in treating glioblastoma. Sci Transl
Med. 13(eabe7378)2021.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Meister H, Look T, Roth P, Pascolo S,
Sahin U, Lee S, Hale BD, Snijder B, Regli L, Ravi VM, et al:
Multifunctional mRNA-based CAR T cells display promising antitumor
activity against glioblastoma. Clin Cancer Res. 28:4747–4756.
2022.PubMed/NCBI View Article : Google Scholar
|
|
168
|
Maggs L, Cattaneo G, Dal AE, Moghaddam AS
and Ferrone S: CAR T cell-based immunotherapy for the treatment of
glioblastoma. Front Neurosci. 15(662064)2021.PubMed/NCBI View Article : Google Scholar
|
|
169
|
Wang D, Starr R, Chang WC, Aguilar B,
Alizadeh D, Wright SL, Yang X, Brito A, Sarkissian A, Ostberg JR,
et al: Chlorotoxin-directed CAR T cells for specific and effective
targeting of glioblastoma. Sci Transl Med.
12(eaaw2672)2020.PubMed/NCBI View Article : Google Scholar
|
|
170
|
Agliardi G, Liuzzi AR, Hotblack A, De Feo
D, Núñez N, Stowe CL, Friebel E, Nannini F, Rindlisbacher L,
Roberts TA, et al: Intratumoral IL-12 delivery empowers CAR-T cell
immunotherapy in a pre-clinical model of glioblastoma. Nat Commun.
12(444)2021.PubMed/NCBI View Article : Google Scholar
|
|
171
|
Brown CE, Rodriguez A, Palmer J, Ostberg
JR, Naranjo A, Wagner JR, Aguilar B, Starr R, Weng L, Synold TW, et
al: Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells
for treatment of glioblastoma. Neuro Oncol. 24:1318–1330.
2022.PubMed/NCBI View Article : Google Scholar
|
|
172
|
Wang G, Zhang Z, Zhong K, Wang Z, Yang N,
Tang X, Li H, Lu Q, Wu Z, Yuan B, et al: CXCL11-armed oncolytic
adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram
tumor microenvironment in glioblastoma. Mol Ther. 31:134–153.
2023.PubMed/NCBI View Article : Google Scholar
|
|
173
|
Ghouzlani A, Kandoussi S, Tall M, Reddy
KP, Rafii S and Badou A: Immune checkpoint inhibitors in human
glioma microenvironment. Front Immunol. 12(679425)2021.PubMed/NCBI View Article : Google Scholar
|
|
174
|
Gatto L, Franceschi E, Di Nunno V, Maggio
I, Lodi R and Brandes AA: Engineered CAR-T and novel CAR-based
therapies to fight the immune evasion of glioblastoma: Gutta cavat
lapidem. Expert Rev Anticancer Ther. 21:1333–1353. 2021.PubMed/NCBI View Article : Google Scholar
|
|
175
|
Bryukhovetskiy I: Cell-based immunotherapy
of glioblastoma multiforme. Oncol Lett. 23(133)2022.PubMed/NCBI View Article : Google Scholar
|
|
176
|
Baharom F, Ramirez-Valdez RA, Khalilnezhad
A, Khalilnezhad S, Dillon M, Hermans D, Fussell S, Tobin KKS,
Dutertre CA, Lynn GM, et al: Systemic vaccination induces
CD8+ T cells and remodels the tumor microenvironment.
Cell. 185:4317–4332.e15. 2022.PubMed/NCBI View Article : Google Scholar
|
|
177
|
Liau LM, Ashkan K, Brem S, Campian JL,
Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, et
al: Association of autologous tumor lysate-loaded dendritic cell
vaccination with extension of survival among patients with newly
diagnosed and recurrent glioblastoma: A phase 3 prospective
externally controlled cohort trial. JAMA Oncol. 9:112–121.
2023.PubMed/NCBI View Article : Google Scholar
|
|
178
|
Keskin DB, Anandappa AJ, Sun J, Tirosh I,
Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E,
et al: Neoantigen vaccine generates intratumoral T cell responses
in phase Ib glioblastoma trial. Nature. 565:234–239.
2019.PubMed/NCBI View Article : Google Scholar
|
|
179
|
Chen KS, Reinshagen C, Van Schaik TA,
Rossignoli F, Borges P, Mendonca NC, Abdi R, Simon B, Reardon DA,
Wakimoto H and Shah K: Bifunctional cancer cell-based vaccine
concomitantly drives direct tumor killing and antitumor immunity.
Sci Transl Med. 15(eabo4778)2023.PubMed/NCBI View Article : Google Scholar
|
|
180
|
Wang J, Weiss T, Neidert MC, Toussaint NC,
Naghavian R, Sellés Moreno C, Foege M, Tomas Ojer P, Medici G,
Jelcic I, et al: Vaccination with designed neopeptides induces
intratumoral, cross-reactive CD4+ T-cell responses in glioblastoma.
Clin Cancer Res. 28:5368–5382. 2022.PubMed/NCBI View Article : Google Scholar
|
|
181
|
Yu TW, Chueh HY, Tsai CC, Lin CT and Qiu
JT: Novel GM-CSF-based vaccines: One small step in GM-CSF gene
optimization, one giant leap for human vaccines. Hum Vaccin
Immunother. 12:3020–3028. 2016.PubMed/NCBI View Article : Google Scholar
|
|
182
|
Li L, Zhou J, Dong X, Liao Q, Zhou D and
Zhou Y: Dendritic cell vaccines for glioblastoma fail to complete
clinical translation: Bottlenecks and potential countermeasures.
Int Immunopharmacol. 109(108929)2022.PubMed/NCBI View Article : Google Scholar
|
|
183
|
Liau LM, Ashkan K, Tran DD, Campian JL,
Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, et
al: First results on survival from a large phase 3 clinical trial
of an autologous dendritic cell vaccine in newly diagnosed
glioblastoma. J Transl Med. 16(142)2018.PubMed/NCBI View Article : Google Scholar
|
|
184
|
Zhu P, Li SY, Ding J, Fei Z, Sun SN, Zheng
ZH, Wei D, Jiang J, Miao JL, Li SZ, et al: Combination
immunotherapy of glioblastoma with dendritic cell cancer vaccines,
anti-PD-1 and poly I:C. J Pharm Anal. 13:616–624. 2023.PubMed/NCBI View Article : Google Scholar
|
|
185
|
Medikonda R, Dunn G, Rahman M, Fecci P and
Lim M: A review of glioblastoma immunotherapy. J Neurooncol.
151:41–53. 2021.PubMed/NCBI View Article : Google Scholar
|
